EA202092030A1 - Офтальмологическая композиция, включающая диквафозол и катионный полимер - Google Patents

Офтальмологическая композиция, включающая диквафозол и катионный полимер

Info

Publication number
EA202092030A1
EA202092030A1 EA202092030A EA202092030A EA202092030A1 EA 202092030 A1 EA202092030 A1 EA 202092030A1 EA 202092030 A EA202092030 A EA 202092030A EA 202092030 A EA202092030 A EA 202092030A EA 202092030 A1 EA202092030 A1 EA 202092030A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cationic
copolymer
hydrolyzed
polymer
ophthalmic composition
Prior art date
Application number
EA202092030A
Other languages
English (en)
Russian (ru)
Inventor
Киохеи Такахаси
Хироюки Асада
Асука Камимура
Кендзи Морисима
Юсуке Момокава
Кенити Эндо
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA202092030A1 publication Critical patent/EA202092030A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EA202092030A 2018-02-28 2019-02-27 Офтальмологическая композиция, включающая диквафозол и катионный полимер EA202092030A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (1)

Publication Number Publication Date
EA202092030A1 true EA202092030A1 (ru) 2020-11-16

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092030A EA202092030A1 (ru) 2018-02-28 2019-02-27 Офтальмологическая композиция, включающая диквафозол и катионный полимер

Country Status (14)

Country Link
US (1) US20210000844A1 (cg-RX-API-DMAC10.html)
EP (1) EP3760207A4 (cg-RX-API-DMAC10.html)
JP (5) JP6716800B2 (cg-RX-API-DMAC10.html)
KR (3) KR20250053220A (cg-RX-API-DMAC10.html)
CN (2) CN117137866A (cg-RX-API-DMAC10.html)
BR (1) BR112020017661A2 (cg-RX-API-DMAC10.html)
CA (1) CA3091700A1 (cg-RX-API-DMAC10.html)
EA (1) EA202092030A1 (cg-RX-API-DMAC10.html)
MX (2) MX2020008925A (cg-RX-API-DMAC10.html)
PH (1) PH12020551313B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202007977RA (cg-RX-API-DMAC10.html)
TW (4) TW202600146A (cg-RX-API-DMAC10.html)
UA (1) UA129517C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019168023A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
WO2020175525A1 (ja) * 2019-02-27 2020-09-03 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
WO2023054669A1 (ja) * 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
JP2024043685A (ja) * 2022-09-20 2024-04-02 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のpHの低下を抑制する方法
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
CA2295515C (en) 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
KR101389300B1 (ko) * 2005-02-14 2014-04-25 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
MX2010009857A (es) * 2008-03-07 2010-12-07 Sun Pharma Advanced Res Co Ltd Composicion oftalmica.
AU2011350762B2 (en) * 2010-12-28 2017-04-06 Santen Pharmaceutical Co., Ltd. Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
MY169816A (en) * 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
EP3139903B1 (en) * 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
WO2015190483A1 (ja) * 2014-06-10 2015-12-17 ロート製薬株式会社 眼科用水性組成物
EA034517B1 (ru) * 2014-12-25 2020-02-17 Сантен Фармасьютикал Ко., Лтд. Водный офтальмологический раствор
KR101587385B1 (ko) 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
JP2017043607A (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
DK3266446T3 (en) * 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
BR112019018368B1 (pt) * 2017-04-25 2021-03-02 Wakamoto Pharmaceutical Co.,Ltd composição oftálmica aquosa
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
WO2020175525A1 (ja) * 2019-02-27 2020-09-03 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Also Published As

Publication number Publication date
KR20220163519A (ko) 2022-12-09
CA3091700A1 (en) 2019-09-06
US20210000844A1 (en) 2021-01-07
JP2020138980A (ja) 2020-09-03
SG11202007977RA (en) 2020-09-29
JPWO2019168023A1 (ja) 2020-05-28
JP7796782B2 (ja) 2026-01-09
JP6716800B2 (ja) 2020-07-01
TWI781296B (zh) 2022-10-21
TW202423451A (zh) 2024-06-16
MX2020008925A (es) 2020-10-01
JP2026034664A (ja) 2026-02-27
UA129517C2 (uk) 2025-05-21
TWI833406B (zh) 2024-02-21
EP3760207A1 (en) 2021-01-06
CN111757742A (zh) 2020-10-09
PH12020551313B1 (en) 2024-02-28
MX2022014791A (es) 2023-01-16
TWI898399B (zh) 2025-09-21
TW202600146A (zh) 2026-01-01
JP7297718B2 (ja) 2023-06-26
TW202000212A (zh) 2020-01-01
JP2024045506A (ja) 2024-04-02
CN111757742B (zh) 2023-09-26
KR102796051B1 (ko) 2025-04-14
KR20200127002A (ko) 2020-11-09
PH12020551313A1 (en) 2021-09-06
JP7472202B2 (ja) 2024-04-22
TW202306572A (zh) 2023-02-16
BR112020017661A2 (pt) 2020-12-22
WO2019168023A1 (ja) 2019-09-06
CN117137866A (zh) 2023-12-01
KR102472773B1 (ko) 2022-11-30
JP2022136152A (ja) 2022-09-15
EP3760207A4 (en) 2023-10-04
KR20250053220A (ko) 2025-04-21

Similar Documents

Publication Publication Date Title
MX2022014791A (es) Composicion oftalmica que comprende dicuafosol y polimero cationico.
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
CL2018002825A1 (es) Vacuna contra vrs
JOP20210106A1 (ar) بروتينات rsv f سابقة الاندماج مستقرة
BR112019000178A2 (pt) hidrogéis de silicone compreendendo n-alquil metacrilamidas e lentes de contato produzidas a partir dos mesmos
BR112019000236A2 (pt) hidrogéis de silicone compreendendo poliamidas
EA202092718A1 (ru) Композиции для контроля патогенов и пути их применения
EP4171457A4 (en) EYE MASK SYSTEM
BR112017018491A2 (pt) hidrolisados de proteína à base de leite e composições produzidas a partir dos mesmos
WO2004004757A8 (en) Treatment for eye disorder
FR3052977B1 (fr) Composition comprenant au moins un polymere acrylate et au moins une silicone choisie parmi les silicones fonctionalisees par au moins un groupement mercapto ou thiol
BR112019006346A2 (pt) composições cosméticas para os cabelos e métodos para o tratamento dos cabelos e para conferir aos cabelos um ou mais efeitos de cuidado dos cabelos
EP4424374A3 (en) Crystalline forms of tenofovir alafenamide
MY197057A (en) Method for producing silicone hydrogel contact lenses
CY1124640T1 (el) Μια meθοδος αντιμετωπισης μυκητιασικων μολυνσεων
EA201990864A1 (ru) Конструкции для экспрессии фратаксина
EA202191686A1 (ru) Гидролизат коллагена для применения против кожных болезней и кишечных заболеваний
PT3660545T (pt) Composição de hidrogel de silicone, lente de hidrogel de silicone, e método de fabrico de lente de hidrogel de silicone
BR112015028726A2 (pt) sistema e método para programar uma lente oftálmica energizada
BR112018072818A2 (pt) copolímero de bloco de silicone, processo para preparação de um copolímero, emulsão, método para tratamento de um substrato, composição para cuidados pessoais, xampu, condicionador para cabelos, uso da emulsão, e, composição anidra de tratamento capilar sem enxágue
MX389361B (es) Ensamble que consiste de un par de implantes oculares multifocales
BR0204921A (pt) Uso de silicones aminados particulares em pré- ou pós-tratamento de descoloração de fibras queratìnicas e processo de descoloração das mesmas
EP3905987A4 (en) DENTAL IMPLANTS, DENTAL IMPLANT SYSTEMS, AND METHODS OF MAKING AND USE THEREOF
EP3829489A4 (en) EYE SURGICAL INJECTOR SYSTEM